CRISPR Therapeutics (CRSP) total liabilities

Total liabilities · fiscal 2025
$343.43M

CRISPR Therapeutics (CRSP) had total liabilities of $343.43M at the end of fiscal 2025 (December 31, 2025). That is 10.8% higher than the $309.95M of fiscal 2024. Figures as of 19 Nov 2026, 03:24 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Total liabilities, fiscal 2025
$343.43M
Change on fiscal 2024
+10.8%
Growth, 5 years
+16.0% a year
Growth, 10 years
+10.7% a year
Highest on record
$367.58Mfiscal 2022
Lowest on record
$83.51Mfiscal 2017
Fiscal years on record
112015–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

CRISPR Therapeutics total liabilities, in more detail

Over the five fiscal years to 2025 total liabilities grew at a compound 16.0% a year; over ten years the rate was 10.7% a year. Across the 11 fiscal years on record (2015–2025), the highest was $367.58M in fiscal 2022 and the lowest $83.51M in fiscal 2017.

History · 11 fiscal years

Total liabilities by fiscal year

CRISPR Therapeutics total liabilities, year by year

CRISPR Therapeutics (CRSP) total liabilities by fiscal year
Fiscal yearTotal liabilitiesChangeYear ended
2025$343.43M 10.8% up
2024$309.95M 10.6% down
2023$346.77M 5.7% down
2022$367.58M 4.3% up
2021$352.42M 115.2% up
2020$163.73M 28.6% up
2019$127.33M 31.5% up
2018$96.82M 15.9% up
2017$83.51M 25.5% down
2016$112.12M 9.6% down
2015$124.03M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest.

How to read it

It is broader than debt: read it against total assets, and remember that for a bank or an insurer customer deposits and policy reserves are liabilities too.

Total liabilities at health care companies of similar size

Total liabilities of CRISPR Therapeutics and comparable companies
CompanyTotal liabilitiesFiscal year
MiniMed Group MMED$1.02B2026
Adaptive Biotechnologies ADPT$287.74M2025
Heartflow HTFL$58.81M2025
CRISPR Therapeutics CRSP$343.43M2025
Travere Therapeutics TVTX$490.36M2025
Option Care Health OPCH$2.13B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on CRSP

CRISPR Therapeutics, figure by figure

CRISPR Therapeutics (CRSP) overview: price, valuation and scorecardAll health care companies by market value

CRISPR Therapeutics total liabilities: questions and answers

How large are CRISPR Therapeutics's total liabilities?

CRISPR Therapeutics (CRSP) had total liabilities of $343.43M at the end of fiscal 2025 (December 31, 2025). That is 10.8% higher than the $309.95M of fiscal 2024.

What is the growth rate of CRISPR Therapeutics's total liabilities?

Over the five fiscal years to 2025 total liabilities grew at a compound 16.0% a year; over ten years the rate was 10.7% a year.

What are the highest and lowest total liabilities figures on record for CRISPR Therapeutics?

Across the 11 fiscal years on record (2015–2025), the highest was $367.58M in fiscal 2022 and the lowest $83.51M in fiscal 2017.

How is CRISPR Therapeutics's total liabilities calculated?

Total liabilities is everything the company owes at the fiscal year-end — borrowings, payables, deferred revenue, lease and pension obligations and the rest. For CRISPR Therapeutics it is on record here for 11 fiscal years, 2015 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “CRISPR Therapeutics (CRSP) total liabilities”, data as of 19 November 2026. https://funkfolio.com/stock/CRSP/total-liabilities

Underlying data: the company's filings with the SEC and Yahoo Finance.